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Venous neointimal hyperplasia (VNH) is responsible for
hemodialysis vascular access malfunction. Here we tested
whether VNH formation occurs, in part, due to vascular
endothelial growth factor-A (VEGF-A) and matrix
metalloproteinase (MMP)-9 gene expression causing
adventitial fibroblast transdifferentiation to myofibroblasts
(a-SMA-positive cells). These cells have increased proliferative
and migratory capacity leading to VNH formation.
Simvastatin was used to decrease VEGF-A and MMP-9 gene
expression in our murine arteriovenous fistula model created
by connecting the right carotid artery to the ipsilateral
jugular vein. Compared to fistulae of vehicle-treated mice,
the fistulae of simvastatin-treated mice had the expected
decrease in VEGF-A and MMP-9 but also showed a significant
reduction in MMP-2 expression with a significant decrease in
VNH and a significant increase in the mean lumen vessel
area. There was an increase in terminal deoxynucleotidyl
transferase dUTP nick-end labeling (TUNEL) staining, and
decreases in a-SMA density, cell proliferation, and HIF-1a and
hypoxyprobe staining. This latter result prompted us to
determine the effect of simvastatin on fibroblasts subjected
to hypoxia in vitro. Simvastatin-treated fibroblasts had a
significant decrease in myofibroblast production along with
decreased cellular proliferation, migration, and MMP-9
activity but increased caspase 3 activity suggesting increased
apoptosis. Thus, simvastatin results in a significant reduction
in VNH, with increase in mean lumen vessel area by
decreasing VEGF-A/MMP-9 pathway activity.
Kidney International (2013) 84, 338–352; doi:10.1038/ki.2013.112;
published online 1 May 2013
KEYWORDS: arteriovenous fistula; chronic kidney disease; murine model;
restenosis; veins
In the United States, approximately 600,000 patients have
end-stage renal disease, with the vast majority of patients
requiring chronic hemodialysis for long-term survival, and
this population of patients will double in the coming
decades.1 Arteriovenous fistula (AVF) is the preferred
vascular access; however, venous stenosis formation and
lack of maturation are major problems, and thus 1-year
patency rates are estimated to be 62%.2 Venous stenosis
occurs in AVFs because of neointimal hyperplasia.3–5
Histologic analysis of AVF specimens reveals that there is
angiogenesis located within the neointima and adventitia of
the vessel, accompanied by increased proliferation of cells
staining positive for a-smooth muscle actin (a-SMA) in the
neointima.3–5 Recent experimental studies have demonstrated
a pivotal role for adventitial and medial fibroblasts that
convert to myofibroblasts (a-SMA-positive cells) and can
subsequently contribute to the formation of venous
neointimal hyperplasia.6–8 As a consequence, over a billion
dollars are spent annually to maintain the function-
ing of hemodialysis AVFs and grafts.1 Effective, non-
invasive treatments, which would prevent and/or reduce
AVF stenosis, could greatly benefit patients with end-stage
renal disease.
Vascular endothelial growth factor-A (VEGF-A) has been
shown to be involved in the pathogenesis of arterial stenosis,
vein bypass grafts, and venous neointimal hyperplasia
associated with hemodialysis vascular access.5,9–18 Previous
work from our laboratory and other laboratories has
demonstrated increased expression of VEGF-A and other
profibrotic genes, including matrix metalloproteinase-2
(MMP-2) and metalloproteinase-9 (MMP-9), at the site
of venous stenosis in murine and porcine models of
hemodialysis AVF and AV graft failure. However, the
mechanism(s) through which VEGF-A and MMPs have a
role in venous neointimal hyperplasia formation has not been
carefully investigated.17,19
Our investigations were performed in a murine model of
chronic kidney disease in animals with an AVF. Simvastatin
has been shown to decrease VEGF-A and MMP expres-
sion.20–22 We tested the hypothesis that the reduction of
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VEGF-A and MMP-9 gene expression via systemic delivery
of simvastatin before the placement of an AVF leads to
a reduction in venous neointimal hyperplasia with
positive vascular remodeling. Gene and protein expression
studies, as well as histomorphometric analyses, were
performed at the outflow vein removed from animals
treated with either simvastatin or controls. We ascertained
whether simvastatin reduces fibroblast to myofibroblast
(a-smooth muscle actin–positive cells) differentiation
induced by hypoxia, and we determined its effect on several
important cellular functions including proliferation and
migration, with increased caspase 3 activity and decreased
MMP-9 activity.
RESULTS
Surgical outcomes
Sixty-nine male C57BL/6 mice weighing 25–30 g were used
for the study. Five mice died after nephrectomy, and two
mice (control) had thickened arteries at the time of
AVF placement and were excluded. Therefore, 62 mice
comprise this study18,19 (Figure 1a and b). Either 40mg/g
of simvastatin (SV, n¼ 35) or phosphate-buffered saline only
(control, C, n¼ 27) was given intraperitoneally every other
day starting 1 week before fistula placement until the time of
killing (Figure 1c).
Serum BUN and creatinine after nephrectomy
The serum blood urea nitrogen (BUN) and creatinine was
used to assess the kidney function. After nephrectomy, the
average BUN was significantly higher for the simvastatin and
the control group at all time points (Po0.001) when
compared with baseline (Figure 1d). At 5 to 8 weeks after
nephrectomy, the average BUN was significantly higher in the
control group when compared with the simvastatin group
(Figure 1e). At 8 weeks after nephrectomy only, the average
serum BUN was significantly higher in the control group
when compared with the simvastatin group (Po0.001). At
8 weeks after nephrectomy, the average serum creatinine was
significantly increased in the control group when compared
with the simvastatin group (Po0.001).
Simvastatin-treated vessels have a significant reduction in
average gene expression of VEGF-A at the outflow vein at
days 7 and 14
VEGF-A expression is increased in failed hemodialysis
vascular accesses (AV fistulas or AV grafts) and in experi-
mental animal models.5,6,17,18 By day 7, the mean gene
expression of VEGF-A at the simvastatin-treated vessels was
significantly lower than the control vessels (average
reduction: 44%, Po0.01 (Figure 2a)), and also at day 14
(average reduction: 49%, Po0.01). Taken collectively, these
results indicate that the average gene expression of VEGF-A is
reduced at the outflow vein in simvastatin-treated vessels
when compared with control vessels.
Simvastatin-treated vessels have a significant reduction
in gene expression of MMP-9 at the outflow vein at
days 7 and 14
Studies have shown increased expression of MMP-9 in failed
hemodialysis vascular accesses (AV fistulas or AV grafts) and
in experimental animal models.6,17,23 By day 7, the average
gene expression of MMP-9 was significantly lower in the
simvastatin-treated vessels when compared with controls
(average reduction: 69%, Po0.0001 (Figure 2b)), and also at
day 14 (average reduction: 41%, Po0.0001). Overall, these
results indicate that simvastatin-treated vessels have a
significant reduction in MMP-9 when compared with control
vessels.
Because the expression of the protein can lag behind
the gene expression, we performed zymography at day 14
to assess MMP-2 and MMP-9 activity in simvastatin-treated
vessels as compared with controls (Figure 2c). There
was significant reduction in both the MMP-9 and MMP-2
activity in the simvastatin-treated vessels when compared
with controls (MMP-9—average reduction: 18%, Po0.01
(Figure 2d); pro-MMP-2—average reduction: 33%,
Po0.0001; and active MMP-2—average reduction: 18%,
Po0.0001 (Figure 2e)).
Kidneys in simvastatin-treated animals have decreased gene
expression of VEGF-A, MMP-2, and MMP-9 at 4 weeks
Because we observed a decrease in average serum BUN and
creatinine in the simvastatin-treated animals when compared
with controls at 8 weeks, we determined whether the
improvement in kidney function was due to a decrease in
genes implicated in causing chronic kidney disease, such
as VEGF-A (Figure 2f), MMP-2 (Figure 2g), and MMP-9
(Figure 2h). The average gene expression of VEGF-A, MMP-2,
and MMP-9 was significantly reduced at day 28 (VEGF-A—
average reduction: 24%, Po0.01; MMP-2—average reduc-
tion: 42%, Po0.001; and MMP-9—average reduction: 57%,
Po0.01) in the simvastatin-treated kidneys when compared
with controls.
Simvastatin-treated vessels have positive vascular
remodeling at days 14 and 28
On hematoxylin- and eosin-stained sections, we were able to
differentiate between the neointima and media/adventitia
(Figure 3a). Semiquantitative histomorphometric analysis
was performed on sections removed from the outflow veins
of simvastatin-treated vessels and control vessels for the
following: the area of the neointima (Figure 3b), media/
adventitia (Figure 3c), and lumen vessel (Figure 3d). There
was a significant reduction in the average area of the
neointima of the simvastatin-treated vessels when compared
with the controls by days 14 to 28 (average reduction: 56%,
Po0.0001; day 28—average reduction: 45%, Po0.001). By
day 14, the average area of the media/adventitia was
significantly lower in the simvastatin-treated vessels when
compared with the control group (average reduction: 43%,
P¼ 0.0028).
R Janardhanan et al.: Simvastatin reduces venous stenosis formation bas i c resea rch
Kidney International (2013) 84, 338–352 339
As the simvastatin-treated vessels had reduced average wall
area when compared with controls, we wanted to determine
whether the simvastatin-treated vessels had a larger average
lumen vessel area (Figure 3d). By days 14 to 28, the average
lumen vessel area was significantly higher in the simvastatin-
treated vessels when compared with controls (average
increase: 150%, Po0.001; day 28—average increase: 343%,
Po0.001).
Because VEGF-A is necessary for cellular homeostasis, we
determined the cell density in the neointima (Figure 3e) and
media/adventitia (Figure 3f). By days 14 and 28, the average
cell density of the neointima and media/adventitia in the
simvastatin-treated vessels was significantly lower than the
control vessels (neointima—day 14: average reduction: 65%,
Po0.0001; day 28: average reduction: 70%, Po0.001; media/
adventitia—day 14: average reduction: 37%, Po0.001; day
28: average reduction: 35%, Po0.01).
Simvastatin-treated vessels have decreased cellular
proliferation at the outflow vein at days 14 and 28
VEGF-A and MMPs are needed for cells to proliferate, and
cellular proliferation was assessed using Ki-67 (brown-stained
nuclei (Figure 4a)). By days 14 and 28, in the simvastatin-
treated vessels, when compared with control vessels, the
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Figure 1 | Overview of study. (a) The nephrectomy procedure is shown, and (b) the placement of the arteriovenous fistula (AVF) is
demonstrated. (c) The study schema. (d) Average serum blood urea nitrogen (BUN) levels after nephrectomy. SV is the simvastatin group and C
is the control group. There was a significant increase in the average BUN values after nephrectomy for the C and SV groups (Po0.001). For the
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Figure 2 | Gene expression levels of vascular endothelial growth factor (VEGF)-A and matrix metalloproteinases (MMPs) are reduced in
simvastatin (SV)-treated vessels and kidneys when compared with controls (Cs). Real-time polymerase chain reaction (RT-PCR) analysis of
(a) VEGF-A and (b) MMP-9 expression after treatment with either C or SV at day 7 or day 14 after arteriovenous fistula (AVF) placement. RT-PCR
analysis of (c) VEGF-A, and (d) MMP-2 and MMP-9 expression after treatment with either C or SV at day 7 or day 28 after AVF placement.
A typical blot showing the RT-PCR bands from 18S and the genes of interest are shown in a, b, and f–h. (a) The average VEGF-A expression is
significantly decreased in the SV-treated vessels when compared with Cs by days 7 and 14 (both Po0.01). (b) The average MMP-9 expression is
significantly decreased at days 7 (Po0.0001) and 14 (Po0.0001) in the SV-treated vessels when compared with Cs. (c) The upper panel
is a typical zymogram from the outflow vein 14 days after treatment with SV or C. In d, there is significant reduction in the average MMP-9
activity in the SV-treated vessels when compared with C vessels (Po0.01). In e, there is significant reduction in the average pro- and active
MMP-2 activity in the SV-treated vessels when compared with C vessels (both Po0.01). (f) The immunostaining of VEGF-A, MMP-2, and
MMP-9 with decreased immunoreactivity qualitatively at days 14 and 28 for MMP-2 and MMP-9 and VEGF-A by day 14 in SV-treated vessels
when compared with C. (g) The average VEGF-A expression is significantly decreased at day 28 in the SV-treated kidneys when compared
with Cs (Po0.01), whereas in h, there is a significant reduction in the average MMP-2 expression in the SV-treated kidneys when compared with
Cs (Po0.001). (i) The average MMP-9 is significantly decreased at days 7 (Po0.001) and 28 (Po0.0001) in the SV-treated kidneys when
compared with Cs. Each bar represents mean±s.e.m. of 3–5 animals. Two-way analysis of variance (ANOVA) followed by Student’s t-test
with post hoc Bonferroni’s correction was performed. Significant differences between simvastatinSV-treated group and Cs are indicated by
*Po0.01, **Po0.001, and #Po0.0001.
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average Ki-67 density was significantly reduced (day 14:
average reduction: 66%, Po0.001; day 28: average reduction:
76%, Po0.0001 (Figure 4b)).
Simvastatin-treated vessels have increased TUNEL staining at
days 14 and 28
Current literature suggests that VEGF-A is needed for main-
taining cellular homeostasis; therefore, we hypothesized that the
decrease in cell density was due to an increase in apoptosis.24
Apoptosis was assessed using terminal deoxynucleotidyl trans-
ferase dUTP nick-end labeling (TUNEL) staining (Figure 5a).
By days 14 to 28, the average density of cells staining positive for
TUNEL (brown) at the outflow vein of the simvastatin group
was significantly higher than the control group (day 14: average
increase: 366%, Po0.0001; day 28: average increase: 561%,
Po0.0001 (Figure 5b)). Overall, these results indicate that
simvastatin-treated vessels have increased TUNEL activity
implying cellular apoptosis when compared with controls.
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Figure 3 | Hematoxylin and eosin (H and E) staining of the simvastatin (SV)-treated vessels showing reduced venous neointimal
hyperplasia and positive vascular remodeling. (a) The representative section after H and E staining at the venous stenosis of either control
(C) or SV at day 14 or day 28 after arteriovenous fistula (AVF) placement. Upper panels, original magnification: 10, and lower panels, original
magnification: 40. ADV, adventitia/media; L, lumen; NI, neointima. (b) The semiquantitative analysis that shows a significant decrease in the
average area of the neointima of the SV-treated vessels when compared with the C group for days 14 (Po0.0001) and 28 (Po0.001). (c) The
semiquantitative analysis that shows a significant decrease in the average area of the media/adventitia of the SV-treated vessels when
compared with the C group for day 14. (d) A significant increase in the average lumen vessel area of the SV-treated vessels when compared
with the C group for days 14 and 28 (Po0.001). (e) A significant decrease in the average cell density in the neointima of the SV-treated vessels
when compared with the C group for days 14 (Po0.0001) and 28 (Po0.001). (f) Similar results in that there is a significant reduction in the
average cell density in the media/adventitia of the SV-treated vessels when compared with the C group for days 14 (Po0.001) and 28 (Po0.01).
Each bar represents mean±s.e.m. of 3–4 animals. Two-way analysis of variance (ANOVA) followed by Student’s t-test with post hoc Bonferroni’s
correction was performed. Significant differences between the SV-treated group and Cs are indicated by *Po0.01, **Po0.001, or #Po0.0001.
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Simvastatin-treated vessels have decreased a-SMA,
smoothelin, and smooth muscle myosin heavy-chain
expression by days 14 and 28
The majority of cells that comprise the venous neointimal
hyperplasia are a-SMA positive (brown-stained cells), and we
determined whether the decrease in the cell density was due
to a decrease in a-SMA-positive cells (Figure 6a). The average
a-SMA density at the outflow vein of simvastatin-treated
vessels was significantly lower than the control group by
day 14 (average reduction: 46%, Po0.0001 (Figure 6b)).
Smooth muscle myosin heavy chain (SMHC) and smoothelin
are expressed by contractile smooth muscle cells. Qualita-
tively, by day 28, there was decreased staining for both
smoothelin and SMHC in the simvastatin-treated vessels
when compared with controls, which suggests a decrease in
contractile smooth muscle cells along with myofibroblasts
(Figure 6a).
Simvastatin-treated vessels have reduced gene expression of
CTGF at day 14
Several genes including connective tissue growth factor
(CTGF) control the regulation of extracellular matrix. We
assessed the gene expression of CTGF using real-time
polymerase chain reaction (RT-PCR) analysis performed at
different time points. The mean gene expression of CTGF
(Figure 7a) at the simvastatin-treated vessels was significantly
lower than the control vessels by day 14 (average reduction:
45%, Po0.001).
Simvastatin-treated vessels have reduced Sirus red staining
Next, we assessed the changes in extracellular matrix using
Sirus red staining, which allows for the evaluation of collagen
1 and 3. Sirus red staining was performed on outflow vein
sections removed from simvastatin-treated and control
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vessels at day 14 and day 28, respectively (Figure 7b).
Qualitatively, this demonstrated a reduction in the intensity
of Sirus red staining in the simvastatin-treated vessels when
compared with control vessels at both days 14 and 28. This
implies that there is a decrease in constrictive remodeling in
the simvastatin-treated vessels when compared with controls.
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Simvastatin-treated vessels have decreased hypoxyprobe
staining and decreased mRNA levels of HIF-1a
Several studies have demonstrated increased hypoxia-indu-
cible factor HIF-1a expression in animal models of
hemodialysis graft failure and in clinical specimens from
patients with hemodialysis vascular access failure.18,23 The
mean gene expression of HIF-1a (Figure 8a) at the
simvastatin-treated vessels was significantly lower than the
control vessels by day 7 (average reduction: 54%, Po0.001)
and day 14 (average reduction: 54%, Po0.001). We assessed
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Figure 7 | Gene expression of connective tissue growth factor (CTGF) and Picrosirius red staining are reduced in simvastatin
(SV)-treated vessels when compared with controls (Cs). (a) The real-time polymerase chain reaction (RT-PCR) analysis of CTGF expression
after treatment with either C or SV at day 7 or day 14 after arteriovenous fistula (AVF) placement. A typical blot is shown in the upper panel and
the pooled data in the lower panel. (a) The average CTGF expression is significantly decreased at day 14 in the SV-treated vessels when
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Figure 6 | a-Smooth muscle actin (a-SMA), smooth muscle heavy chain (SMHC), and smoothelin staining are decreased in simvastatin-
treated vessels. (a) Representative sections after a-SMA (first column), SMHC (second column), and smoothelin (third column) staining at the
venous stenosis after treatment with either control (C) or simvastatin (SV) at day 14 or day 28 after arteriovenous fistula (AVF) placement.
All are original magnifications 40. Brown-staining cytoplasm is positive for a-SMA, SMHC, or smoothelin. (b) Semiquantitative analysis that
shows a significant decrease in the average a-SMA staining in the SV-treated vessels when compared with the C group for days 14 (Po0.0001)
and 28 (Po0.0001). Qualitatively, by day 28, SMHC and smoothelin staining are reduced in the simvastatin-treated vessels when compared with
Cs. Each bar represents mean±s.e.m. of 3–4 animals. Two-way analysis of variance (ANOVA) followed by Student’s t-test with post hoc
Bonferroni’s correction was performed. Significant differences between the simvastatin-treated group and controls are indicated by *Po0.01
and #Po0.0001.
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HIF-1a staining as well. Cells staining positive for HIF-1a
are brown (Figure 8b). By days 14 to 28, there was a
significant reduction in the average density of HIF-1a
staining in the simvastatin-treated vessels when compared
with controls (day 14: average reduction: 20%, Po0.001;
day 28: average reduction: 36%, Po0.001 (Figure 8c)). We
next performed hypoxyprobe staining in the outflow
vein treated with either simvastatin or controls (Figure 8d).
Cells staining positive for hypoxyprobe are brown. By days 14
to 28, there was a significant reduction in the average
density of hypoxyprobe staining in the simvastatin-treated
vessels when compared with controls (Day 14: average
reduction: 40%, Po0.001; day 28: average reduction: 70%,
Po0.01 (Figure 8e)). Overall, these results indicate that
there is decreased expression of both HIF-1a and hypoxy-
probe in simvastatin-treated vessels when compared with
controls.
Simvastatin treatment in hypoxic fibroblasts reduces a-SMA
production at 24 hours
Studies indicate that hypoxia can cause an increase in
fibroblast to myofibroblast differentiation.25,26 To determine
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when compared with controls (Cs). (a) The real-time polymerase chain reaction (RT-PCR) analysis of HIF-1a expression after treatment with
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are indicated by *Po0.01 or **Po0.001.
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whether simvastatin treatment could decrease the conversion
of fibroblasts to a-SMA-positive cells under hypoxic stress,
we used NIH 3T3 cells, which were treated with 1 mmol/l of
simvastatin (SV) or control (C) and subjected to incubation
for 24 h. We first determined the synthetic phenotype of the
SMC using confocal imaging for phalloidin and a-SMA
(Figure 9a). Cells staining red are positive for a-SMA, and
cells staining green are positive for phalloidin, with the nuclei
staining blue. As shown, this demonstrated a qualitative
reduction in a-SMA plus phalloidin staining for the
simvastatin-treated cells when compared with controls for
both 24 h of normoxia and hypoxia.
Simvastatin treatment reduces proliferation and migration in
hypoxic fibroblasts
We determined whether the proliferative capacity of
simvastatin-treated NIH 3T3 cells is reduced under hypoxia
when compared with controls. This demonstrated that
there was significant reduction in the proliferative ability
of fibroblasts treated with simvastatin as compared with
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indicated by #Po0.0001.
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controls for 24-h hypoxia (average reduction: 70%,
Po0.0001 (Figure 9b)). We next determined whether the
migratory capacity of simvastatin-treated NIH 3T3 cells is
reduced under hypoxia when compared with controls using
a Matrigel invasion assay (Figure 9c). This demonstrated
that the migratory capacity of simvastatin-treated cells was
significantly decreased for simvastatin when compared with
controls for 24-h hypoxia (average reduction: 33%,
Po0.0001 (Figure 9d)). We next determined the effect of
simvastatin on caspase 3 activity on NIH 3T3 cells under
hypoxia and normoxia. We observed a significant increase in
caspase 3 activity in cells treated with simvastatin when
exposed to hypoxia as compared with controls (average
increase: 600%, Po0.0007 (Figure 9e)). Finally, we deter-
mined the effect of simvastatin on the activity of MMP-9 in
NIH 3T3 cells under hypoxia and normoxia at 8 and 24 hours
(Figure 9f). We observed a significant decrease in MMP-9
activity at 8 hours of hypoxia (average reduction: 33%,
Po0.0001 (Figure 9g)) and at 24 hours of normoxia (average
reduction: 33%, Po0.0001 (Figure 9g)).
DISCUSSION
In this study, we demonstrated that the venous stenosis from
the AVF of simvastatin-treated vessels have reduced gene
expression of VEGF-A and MMP-9, with protein expression
of pro- and active MMP-2 and MMP-9 and a significant
reduction in the average area of the neointima and
media/adventitia, as well as positive vascular remodeling.
In simvastatin-treated vessels, we observed a significant
decrease in cellular proliferation, cell density (a-SMA),
smoothelin, and SMHC, and a significant increase in
apoptosis. In addition, a significant decrease in the local
vessel hypoxia was observed, which was confirmed using two
different approaches: HIF-1a and hypoxyprobe staining with
RT-PCR for HIF-1a. Simvastatin-treated vessels had a
decrease in extracellular matrix, with a significant reduction
in CTGF, a profibrotic gene responsible for regulating
extracellular matrix. In vitro experiments showed that NIH
3T3 fibroblasts when exposed to hypoxia and treated with
simvastatin had a decrease in a-smooth muscle cell
expression, proliferation, migration, and MMP-9 activity
with increased caspase 3 activity. These results, taken in
aggregate, indicate pretreatment with simvastatin before the
placement of AVF, and we hypothesize that this results
because of a decrease in fibroblast to myofibroblast
conversion mediated through a VEGF-A/MMP-9 pathway
associated with a decrease in CTGF, resulting in positive
vascular remodeling and decrease in venous neointimal
hyperplasia.
In patients with malfunctioning hemodialysis vascular
access and in experimental animal models of hemodialysis
AVF or graft failure, increased expression of MMP-2 and
MMP-9 has been observed.6,17,18,23,27 Previous studies in
experimental animal models of atherosclerosis,28 arterial
stenosis after angioplasty,29 and saphenous vein bypass
grafting20–22,30 have demonstrated that simvastatin therapy
reduces intimal hyperplasia mediated through an MMP
pathway. Porter et al.20 demonstrated in a saphenous
vein–based organ culture model that MMP-9 expression is
decreased after statin use and is mediated via a Rho A/ROCK
signaling pathway. In this study, we demonstrate that
simvastatin therapy in a murine model of AVF with chronic
kidney disease causes a significant reduction in MMP-9,
which in turn is accompanied by a significant reduction in
the average area of the neointima and media/adventitia and a
concomitant increase in lumen vessel area. These findings are
consistent with experimental studies using a porcine model
of arteriovenous hemodialysis graft failure, in which the
MMP inhibition reduces venous neointimal hyperplasia
formation.31
In addition to MMPs, increased expression of VEGF-A has
been localized to the adventitia and neointima in specimens
removed from patients with failed hemodialysis vascular
access.5 Previous studies from our laboratory in experimental
animal models of venous neointimal hyperplasia formation
in hemodialysis AVF or graft failure have demonstrated that
there is increased expression of VEGF-A at the venous
stenosis when compared with the control vein.18,27
Simvastatin has been shown to decrease VEGF expression
in vascular smooth muscle cells and macrophages, as it relates
to atherosclerosis.20–22,30,32–34 At low doses, simvastatin has
angiogenic properties, and at higher doses, simvastatin has
antiangiogenic properties mediated by decreasing VEGF-A.35,36
Interestingly, in endothelial cells, simvastatin activates Akt,
which is a protein kinase responsible for angiogenesis.37
Indeed, it is well known that Akt signaling is downstream to
VEGF-A activation.38 This protective endothelial effect of
simvastatin is thought to be responsible for the clinical
efficacy observed in patients with vascular disease.39 In this
study, we used a high dose of simvastatin and observed that
simvastatin-treated vessels have decreased expression of
VEGF-A with a decrease in neointimal hyperplasia.40 These
results are consistent with reports in animal models of
arterial stenosis, which have demonstrated that blockade of
VEGF-A using soluble VEGF receptor 1 reduces intimal
hyperplasia.16
On histologic analysis, it was found that venous
neointimal hyperplasia is characterized by an increase in
a-smooth muscle cell staining, cellular proliferation, and
increased extracellular matrix composed primarily of collagen 1
and 3.3–5 Using Ki-67 staining, we observed a significant
decrease in cellular proliferation in simvastatin-treated vessels
when compared with controls. These findings are consistent
with several studies conducted in different vascular injury
models that have demonstrated that simvastatin-treated
vessels have decreased cellular proliferation.20–22,28–30,41
Cellular proliferation can be often accompanied by
changes in cell death as demonstrated by TUNEL staining.
In the simvastatin-treated vessels, when compared with
controls, there was a significant increase in the average
TUNEL staining. These findings are consistent with previous
studies that have demonstrated that there is increased
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TUNEL staining.29,41 Furthermore, the increase in TUNEL
staining was accompanied by a decrease in the average
cellular density. Finally, a significant decrease in a-smooth
muscle cell actin staining was demonstrated in the
simvastatin-treated vessels, consistent with prior studies
utilizing different animal models of vascular
injury.21,22,28,30,42 In addition, we observed a decrease in the
contractile smooth muscle cell phenotype as indicated by a
decrease in staining for smoothelin and SMHC staining.
Picrosirius red staining was performed to assess the
changes in extracellular matrix in vessels treated with
simvastatin, and controls. This demonstrated that there was
a decrease in the intensity of the staining, demonstrating a
decrease in extracellular matrix deposition in the outflow
vein in the simvastatin-treated vessels when compared with
controls. This is consistent with an animal model of
atherosclerosis that demonstrated similar results with sim-
vastatin treatment.28,43 Furthermore, we investigated the
expression of CTGF, which was found to be decreased in
simvastatin-treated vessels when compared with controls. A
recent study demonstrated that simvastatin causes a decrease
in vascular fibrosis mediated through a angiotensin II/Smad
pathway, resulting in a decrease in the expression of CTGF.44
A second study showed that the decrease in CTGF is also
mediated through a Rho pathway in fibroblasts treated with
simvastatin.45
One unanticipated result of systemic simvastatin therapy
was an improvement in kidney function at 5 weeks after
initiation of simvastatin. To determine a potential cause, we
determined the gene expression of VEGF-A, MMP-2, and
MMP-9 in the kidneys of simvastatin-treated animals
compared with controls. Each of these genes have been
implicated in the progression of chronic kidney disease.46 We
observed that by day 28, in the simvastatin-treated kidneys
when compared with controls, there was a significant
reduction in the expression of VEGF-A, MMP-2, and
MMP-9. We postulate that the reduction of these genes
resulted in the improvement in kidney function, which was
consistent with other studies.47
Hypoxic injury is known to accelerate the conversion of
fibroblasts to myofibroblasts, and increased HIF-1a has been
observed in animal models and in clinical specimens of AVF
or graft failure.18,23,25 VEGF-A-mediated activation of
fibroblasts to the myofibroblast phenotype can be
accompanied by activation of matrix regulatory signaling
moieties including MMP-2 and MMP-9.26,48 We used
1 mmol/l concentration of simvastatin, as previous data
indicate that the dose of simvastatin used in our in vivo
experiments is in the range of 1–2mmol/l.49 Fibroblasts
treated with either simvastatin or controls when subjected to
hypoxia had a decrease in a-SMA expression with a
significant decrease in migration and proliferation, as well
as decreased MMP-9 activity and increased caspase 3 activity.
The role of statin therapy has been studied in fibroblasts and
myofibroblasts but not on hypoxia and its role on conversion
of fibroblast to myofibroblasts.20,30,34,50
There are some limitations of this study. First, there was
an improvement in the kidney function at 28 days, which
could explain the decrease in VNH and improvement in the
lumen vessel area.51,52 Second, there are multiple mechanisms
that are affected by simvastatin, and we demonstrate a change
in one of these pathways only. Finally, a recent study has
demonstrated that statin use was not associated with an
improvement in hemodialysis vascular access.53 This study
had several limitations, including the fact that there was no
protocol for the dosing of statins used. In addition, there
were differences in the group of patients who received statins,
and it was not noted which statin was used, as there are
differences in the efficacy of different statins.21
In conclusion, we demonstrate that systemic delivery of
simvastatin is associated with a decrease in the expression of
several important matrix-regulating genes such as VEGF-A,
MMP-2, MMP-9, and CTGF. The net result is an overall
decrease in the venous neointimal hyperplasia with a decrease
in a-SMA-positive cells, migration, proliferation, and an
increased apoptosis with positive vascular remodeling. The
clinical significance of this study is that it provides a rationale
for using simvastatin before the placement of AVF in
reducing venous neointimal hyperplasia formation.
METHODS AND MATERIALS
Experimental animals
Appropriate Institutional Animal Care and Use Committee approval
was obtained before performing any procedures. Sixty-nine male
C57BL/6 mice (Jackson Laboratories, Bar Harbor, ME) weighing
25–30 g were used for this study as depicted (Figure 1). Chronic
kidney disease was created by surgical removal of the right kidney,
accompanied by ligation of the arterial blood supply to the upper
pole of the left kidney as described previously (Figure 1a).18 Three
weeks after nephrectomy, the animals were started on simvastatin
(40mg/kg administered intraperitoneally three times per week) or
phosphate-buffered saline (equal amount of volume used for
simvastatin intraperitoneal controls). Simvastatin was prepared as
described elsewhere.54 A week later, an AVF was created by
connecting the right carotid artery to the ipsilateral jugular vein,
as described previously, and the mice were then killed
(Figure 1b).18,19 Please see Supplementary Methods online for full
details.
Tissue processing and immunohistochemistry
Each outflow vein from each animal was embedded in paraffin
lengthwise, so that the sections would be orthogonal to the long axis
of the vessel (Figure 1b). Typically, 80 to 120, 4-mm sections were
obtained, and the cuff used to make the anastomosis could be
visualized. —Two to four, 40 micrometer sections were stained with
hematoxylin and eosin, Ki-67, a-SMA, hypoxyprobe, HIF-1 a,
smoothelin, SMHC, picrosirius red, or TUNEL. Cellular prolifera-
tion was determined by staining for Ki-67 on sections removed from
the outflow vein by performing quantification at different time
points. Smooth muscle density was determined by staining for
a-SMA on sections removed from the outflow vein by performing
quantification at the different time points. Immunohistochemistry
for Ki-67 and a-SMAwas performed on paraffin-embedded sections
from the outflow vein after transfection with either simvastatin or
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control groups using the EnVision (Dako, Carpinteria, CA) method
with a heat-induced antigen-retrieval step.6,17 The following
antibodies were used: mouse monoclonal antibody Ki-67 (DAKO,
Carpentaria, CA; 1:400), mouse monoclonal HIF-1a (Novus
Biologicals, Littleton, CO; 1:500), rabbit polyclonal antibody to
mouse for a-SMA (Abcam, Cambridge, MA; 1:400), mouse
monoclonal to SMHC (Novus Biologicals; 1:500), or smoothelin
(Santa Cruz Biotechnology, Santa Cruz; 73042; 1:500). IgG antibody
staining was performed to serve as controls.
The outflow vein with the cuff anastomosis was collected as
shown (Figure 1b) and then embedded. In this model, the stenosis
forms at the outflow vein, and this can be identified easily, as the
cuff used to create the anastomosis is a landmark. An average of 12
multiple contiguous serial 4-mm sections were stained with
hematoxylin and eosin and analyzed for histomorphometric
analyses (see later).
Hypoxyprobe staining at days 14 and 28
We assessed hypoxic changes in the outflow vein after treatment
with either simvastatin or controls using HypoxyprobeTM-1
(a substituted derivative of pimonidazole hydrochloride).
HypoxyprobeTM-1 upon activation forms stable covalent adducts
with thiol groups of proteins, peptides, and amino acids of hypoxic
tissue. Please see Supplementary Methods online for full details.
TUNEL staining at days 14 and 28
TUNEL staining was performed on paraffin-embedded sections
from the outflow vein after transfection with either simvastatin or
controls, as specified by the manufacturer (DeadEnd Colorimetric
tunnel assay system, G7360; Promega, Madison, WI).
Picrosirius red staining at days 14 and 28
Picrosirius staining was performed to assess for collagen 1 and 3
depsotion. Please see Supplementary Methods online for full details.
SDS-PAGE zymography for MMP-2 and MMP-9
MMP-2 and MMP-9 protein activities were determined using
zymographic analysis. This was performed on homogenates from
cultured cells or outflow veins treated with simvastatin or control as
described previously.6,17
RT-PCR analysis
Expression for the gene of interest was determined using RT-PCR
analysis.19 Briefly, first-strand cDNA was synthesized using
SuperScript III First Strand (Invitrogen, Carlsbad, CA) according
to the manufacturer’s guidelines. cDNAs specific for the genes
analyzed were amplified using commercial primers purchased from
SA Biosciences (Frederick, MD). Please see Supplementary Methods
online for full details.
Hypoxia chamber
One hundred thousand NIH 3T3 cells were treated with either
simvastatin or controls and then made hypoxic for 8 or 24 hours as
described previously.26
Proliferation assay
One hundred thousand NIH 3T3 cells were treated with either
simvastatin or controls and then seeded in 24-well plates and
cultured for 24 h in Dulbecco’s modified Eagle’s medium. After 20 h,
1mCi of 3H-thymidine was added to each well; 4 h later, cells were
washed with chilled phosphate-buffered saline, fixed with 100% cold
methanol, and collected for measurement of trichloroacetic acid
precipitable for radioactivity. Experiments were repeated at least
three times for each time point.
Cell migration assay
One hundred thousand NIH 3T3 cells were treated with either
simvastatin or controls and were seeded in 8 micrometer trans-wells
precoated with low growth factor Matrigel in a serum-free media.
The complete medium was supplemented under the trans-well and
incubated for 6 h at 37 1C. After 6 h, trans-wells were washed with
phosphate-buffered saline and fixed with paraformaldehye (4%
(v/v)). Finally trans-wells were stained with bromophenol (0.1%)
solution. The cells from the upper side were removed with cotton-
tip applicators. The cells at the bottom side were counted for
analysis.
Morphometry and image analysis
Sections immunostained for hematoxylin and eosin stains were
viewed with an Axioplan 2 Microscope (Zeiss, Oberkochen,
Germany) equipped with a Neo-Fluor 20/0.50 objective and
digitized to capture a minimum of 30903900 pixels using a
Axiocam camera (Zeiss).6,17 Images covering one entire cross-
section from each section of the outflow vein treated with
simvastatin or controls were acquired and analyzed using the KS
400 Image Analysis software (Zeiss). Ki-67 (brown), a-SMA positive
(brown), SMHC (brown), smoothelin (brown), TUNEL positive
(brown), HIF-1a (brown), or hypoxyprobe (brown) were
highlighted, in turn, by selecting the appropriate red–green–blue
color intensity range and then counted. The color intensity was
adjusted for each section to account for the decreasing intensity of
positive staining over time. This was repeated two times to ensure
that the intraobserver variability was o10%. Sections were
subsequently viewed with an Axioplan 2 Microscope (Zeiss)
equipped with a Neo-Fluor 20/0.50 objective and digitized to
capture at least 10301300 pixels, and cell density determined along
with the vessel wall and luminal vessel areas was performed on
12 contiguous sections. The area was measured by tracing the vessel
wall using an automated program.17
Statistical methods
Data are expressed as mean±s.e.m. Multiple comparisons were
performed with two-way analysis of variance, followed by Student’s
t-test with post hoc Bonferroni’s correction. Because of the
Bonferroni correction, significant difference from control value
was indicated by *Po0.01, **Po0.001, or #Po0.0001. SAS version
9 (SAS Institute, Cary, NC) was used for statistical analyses.
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SUPPLEMENTARY MATERIAL
Figure S1. Hematoxylin and eosin (H and E) staining of the
simvastatin-treated vessels showing reduced venous neointimal
hyperplasia and positive vascular remodeling in animals with AVF
and normal kidney function at day 28.
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Supplementary material is linked to the online version of the paper at
http://www.nature.com/ki
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